Health.Global

Which are the latest news on Health.Global?

Why is Healthcare Global Enterprises Ltd falling/rising?

As of 05-Sep, Healthcare Global Enterprises Ltd's stock price is at 700.80, down 0.24%. Despite this minor decline, the stock has shown strong long-term growth and positive performance trends, significantly outperforming the Sensex year-to-date.

As of 05-Sep, Healthcare Global Enterprises Ltd's stock price is currently at 700.80, reflecting a decrease of 1.7 points or 0.24%. Despite this slight decline, the stock has shown positive performance trends over various periods. For instance, in the past week, the stock has increased by 0.74%, and over the last month, it has risen by 5.50%. Year-to-date, the stock has gained 6.44%, significantly outperforming the Sensex, which has fallen by 10.21% during the same timeframe.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 2.28%, and it has experienced consecutive gains over the last two days, with a total return of 1.51% in that period. The stock reached an intraday high of Rs 717.05, marking a 2.07% increase at that point. Additionally, there has been a notable rise in investor participation, with delivery volume increasing by 49.37% compared to the five-day average.<BR><BR>The company has demonstrated strong long-term growth, with operating profit and net profit growing at annual rates of 195.08% and 193.02%, respectively. It has also declared positive results for the last two consecutive quarters, indicating robust financial health. The stock is trading at a discount compared to its peers, and high institutional holdings at 21.94% suggest confidence from more sophisticated investors.<BR><BR>However, the stock's current decline may be attributed to its recent price action, which has seen a slight drop despite the overall positive trends. The company's ability to service its debt is a concern, as indicated by a poor EBIT to Interest ratio of 1.23, which may weigh on investor sentiment. Overall, while the stock is experiencing a minor decline at present, its longer-term performance and positive financial indicators suggest a generally favorable outlook.

Who are in the management team of Health.Global?

The management team of Health.Global includes Basavalinga Ajaikumar Sadashivaiah (Chairman, Executive Director & CEO), Siddharth Patel and Amit Soni (Non-Executive Directors), Anjali Ajaikumar Rossi (Executive Director), and several Independent Non-Executive Directors, along with Sunu Manuel as Company Secretary. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Health.Global includes the following individuals:<BR><BR>1. **Basavalinga Ajaikumar Sadashivaiah** - Chairman, Executive Director & CEO<BR>2. **Siddharth Patel** - Non-Executive Director / Nominating Director<BR>3. **Anjali Ajaikumar Rossi** - Executive Director<BR>4. **Geet Mathur** - Independent Non-Executive Director<BR>5. **Rajagopalan Raghavan** - Independent Non-Executive Director<BR>6. **Pradip M. Kanakia** - Independent Non-Executive Director<BR>7. **Meghraj Arvindrao Gore** - Whole Time Director & CEO<BR>8. **Amit Soni** - Non-Executive Director / Nominating Director<BR>9. **Rajiv Maliwal** - Independent Non-Executive Director<BR>10. **Sunu Manuel** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

What does Health.Global do?

HealthCare Global Enterprises Ltd operates in the hospital industry, focusing on oncology services. As of June 2026, it reported net sales of 695 Cr and a net profit of 14 Cr, with a market cap of INR 10,270 Cr.

Overview:<BR>Healthcare Global Enterprises Ltd operates in the hospital industry and is classified as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as Curie Centre of Oncology Private Limited in 1998. It underwent a name change to HealthCare Global Enterprises Private Limited in 2005 and was converted into a Public Limited Company, adopting its current name in 2006. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 695 Cr (Quarterly Results - Jun 2026)<BR>Net Profit: 14 Cr (Quarterly Results - Jun 2026)<BR>Market Cap: INR 10,270 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 164.00<BR>Industry P/E: 67<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.90<BR>Return on Equity: 4.38%<BR>Price to Book: 7.79<BR><BR>Contact Details:<BR>Address: HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar Bangalore Karnataka : 560027<BR>Tel: 91-80-4660-7700<BR>Email: sunumanuel@hcgoncology.com<BR>Website: http://www.hcgel.com

Who are the peers of the Health.Global?

Health.Global's peers include Narayana Hrudaya, Krishna Institute, Dr. Agarwal's Health, Rainbow Children's Hospital, Jupiter Life Line, Yatharth Hospital, Kovai Medical Center, Jeena Sikho, and Artemis Medicare. In terms of management risk, growth, and capital structure, Narayana Hrudaya and Jeena Sikho show excellent ratings, while Health.Global has below-average capital structure and a 1-year return of 10.66%.

Peers: The peers of Health.Global are Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Jupiter Life Lin, Yatharth Hospit., Kovai Medical, Jeena Sikho, and Artemis Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Narayana Hrudaya, Jupiter Life Lin, and Kovai Medical, while Good management risk is found at Krishna Institu., Rainbow Child., and Yatharth Hospit. Average management risk is present at Dr Agarwal's Hea, Jeena Sikho, and Artemis Medicare, while Below Average management risk is noted at Yatharth Hospit. In terms of Growth, Excellent growth is seen at Narayana Hrudaya and Jeena Sikho, while Good growth is found at Dr Agarwal's Hea, Health.Global, and Artemis Medicare. Below Average growth is noted at Krishna Institu., Rainbow Child., Jupiter Life Lin, and Kovai Medical. Finally, Capital Structure ratings show Excellent at Jupiter Life Lin and Jeena Sikho, Good at Narayana Hrudaya, Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Kovai Medical, and Artemis Medicare, and Below Average at Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dr Agarwal's Hea at 18.31%, while Jeena Sikho has the lowest at -27.85%. Health.Global's 1-year return of 10.66% is higher than Jeena Sikho's but lower than Dr Agarwal's Hea. Additionally, Jeena Sikho and Krishna Institu. have negative six-month returns.

How big is Health.Global?

As of 31st August, Healthcare Global Enterprises Ltd has a market capitalization of 10,270.00 Cr, with recent net sales of 2,627.35 Cr and a net profit of 22.78 Cr.

As of 31st August, Healthcare Global Enterprises Ltd has a market capitalization of 10,270.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,627.35 Cr and a Net Profit of 22.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 922.44 Cr and Total Assets totaling 3,518.24 Cr.

Should I buy, sell or hold Healthcare Global Enterprises Ltd?

When is the next results date for Healthcare Global Enterprises Ltd?

The next results date for Healthcare Global Enterprises Ltd is 06 August 2026.

The next results date for Healthcare Global Enterprises Ltd is on 06 August 2026.

Are Healthcare Global Enterprises Ltd latest results good or bad?

Healthcare Global Enterprises Ltd's latest results are concerning, showing a 70.52% decline in net profit despite an 11.48% increase in net sales. The company's financial challenges, including high interest costs and low return on equity, overshadow its revenue growth.

Healthcare Global Enterprises Ltd's latest results present a mixed picture, leaning towards the negative side. In the fourth quarter of FY26, the company reported consolidated net profit of ₹2.17 crores, which is a significant decline of 70.52% year-on-year. This sharp drop in profitability raises concerns about the company's ability to convert its revenue growth into actual earnings.<BR><BR>On the positive side, net sales reached ₹652.33 crores, reflecting an 11.48% increase year-on-year, which indicates strong revenue generation capabilities. Additionally, the operating margin improved to 19.23%, suggesting better operational efficiency.<BR><BR>However, the stark contrast between rising revenues and plummeting profits highlights serious underlying issues. High interest costs and depreciation, along with a very low return on equity of 3.84%, indicate that the company is struggling to manage its capital effectively. Furthermore, the stock has underperformed compared to its peers in the hospital sector, which raises further concerns about its market position and valuation.<BR><BR>Overall, while there are some positive aspects in terms of revenue growth and operational margins, the significant decline in net profit and the company's financial challenges suggest that the latest results are more concerning than encouraging.

Is Health.Global technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish due to positive daily moving averages and Bollinger Bands, but caution is advised due to mixed signals from the MACD, KST, and monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullishness and the Bollinger Bands showing a mildly bullish signal on both weekly and monthly time frames. However, the MACD and KST on the weekly are mildly bearish, and the monthly RSI is bearish, suggesting some caution. Overall, the mixed signals indicate a mildly bullish outlook with underlying weaknesses that could affect momentum.

Is Health.Global overvalued or undervalued?

As of November 24, 2025, Health.Global is considered undervalued with an attractive valuation grade, despite having a high PE ratio of 286.73 and an EV to EBITDA ratio of 27.53, while outperforming the Sensex with a 53.86% return over the past year.

As of 24 November 2025, Health.Global's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 286.73, an EV to EBITDA ratio of 27.53, and a ROCE of 7.64%. <BR><BR>In the peer comparison, Health.Global's PE ratio significantly exceeds that of Apollo Hospitals, which stands at 63.22, while its EV to EBITDA ratio is also higher than Apollo's 33.25. This suggests that Health.Global may be overvalued on a relative basis despite its attractive grade. Notably, the company's stock has outperformed the Sensex over the past year, returning 53.86% compared to the Sensex's 7.31%, reinforcing the notion of its strong market performance despite the high valuation ratios.

How has been the historical performance of Health.Global?

Health.Global has shown strong growth in net sales, reaching 2,222.85 Cr in March 2025, with operating profit increasing to 387.28 Cr and a margin of 17.46%. However, profit before tax declined to 56.19 Cr, and the company faces cash management challenges despite improved operating cash flow.

Answer:<BR>The historical performance of Health.Global shows a significant upward trend in net sales and operating profit over the past several years, culminating in a net sales figure of 2,222.85 Cr for the year ending March 2025, up from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income has also increased consistently, reaching 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr in March 2025 from 329.59 Cr in March 2024, reflecting a healthy operating profit margin of 17.46%. However, profit before tax decreased to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, slightly up from 40.93 Cr the previous year. <BR><BR>In terms of assets and liabilities, total assets increased to 3,518.24 Cr in March 2025 from 2,700.44 Cr in March 2024, while total liabilities also rose to 3,518.24 Cr, indicating a balanced growth. The company’s total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr in March 2025, although the net cash outflow was recorded at -213.00 Cr, indicating challenges in cash management. Overall, Health.Global has shown growth in sales and operating profit, but faces pressures on profitability and cash flow management.<BR><BR>Breakdown:<BR>Health.Global has demonstrated a robust growth trajectory in net sales, which reached 2,222.85 Cr in March 2025, marking a significant increase from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income mirrored this growth, also hitting 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr, up from 329.59 Cr the previous year, resulting in an operating profit margin of 17.46%. Despite this positive trend, profit before tax saw a decline to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, which is an increase from 40.93 Cr in the prior year. <BR><BR>On the balance sheet, total assets surged to 3,518.24 Cr in March 2025, compared to 2,700.44 Cr in March 2024, while total liabilities matched this figure, indicating a balanced growth. The total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr, yet the company faced a net cash outflow of -213.00 Cr, highlighting ongoing challenges in cash management despite the growth in sales and operating profit.

Who are the top shareholders of the Health.Global?

The top shareholders of Health.Global include Aceso Company Pte. Ltd. with 60.35%, followed by mutual funds at 9.19%, individual investors at 10.43%, and foreign institutional investors at 2.45%. The largest public shareholder is Tata India Pharma & Healthcare Fund, owning 3.42%.

The top shareholders of Health.Global include Aceso Company Pte. Ltd., which holds the largest stake at 60.35%. The promoters are the majority shareholders, with a pledged promoter holding of 4.995%. Additionally, mutual funds hold 9.19% of the shares across 9 schemes, while foreign institutional investors (FIIs) have a combined holding of 2.45% through 85 different entities. The highest public shareholder is Tata India Pharma & Healthcare Fund, which owns 3.42%. Individual investors collectively hold 10.43% of the company's shares.

Has Health.Global declared dividend?

No Dividend History Available